A carregar...
EH1.3 EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine versus lomustine in patients with first progression of a glioblastoma
BACKGROUND: Phase II data from BELOB suggested the combination of bevacizumab and lomustine to produce an overall survival (OS) benefit compared with either monotherapy for patients with progressive glioblastoma. Agnostic to the phase II data of the trial, EORTC 26101 investigated whether the combin...
Na minha lista:
| Publicado no: | Neuro Oncol |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5782502/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now188.002 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|